Table S12. Differentially expressed genes (DEGs) in brain tumor-associated immune cells at 7d, under TMZ and TAT-Cx43 peptide treatments, shown in Figure 7C and Suppl. 6C.
In vitro release profile of eugenol encapsulated in nano-structured lipid carriers and free eugenol solution: Legend: *P<0.05 after two-way ANOVA test. NFE (Nanostructured formulation containing e
Adaptive immunity is a targeted immune response that enables the body to identify and eliminate foreign pathogens, playing a critical role in the anti-tumor immune response. Tumor cell expression of a
